Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists
Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK inhibitors (BTKis) — have been developed as targeted therapies to treat B-cell malignancies1. B-cell malignancies are a type of blood cancer that derive […]
Publication Details
- Journal
- Pharmaceutical journal/The pharmaceutical journal
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1211/pj.2025.1.367256
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00